Lu Meng, Wei Fu-Kun, Wu Chuang, Xu Zi-Yang, Mao Li-Jun, Yang Dong-Rong
Department of Urology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu Province, China.
Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.
J Oncol. 2022 Apr 30;2022:7918067. doi: 10.1155/2022/7918067. eCollection 2022.
Prostate cancer (PCa) is a common malignant tumor of the male urinary system and ranks the second in the causes of tumor-related deaths. Differential display code 3 (DD3) is a noncoding gene that is specifically expressed in PCa. High expression of sperm-associated antigen 9 (SPAG9) is closely related to tumorigenesis of PCa, and SPAG9 is a therapeutic target for PCa. In this study, a new oncolytic adenovirus DD3-ZD55-SPAG9 was constructed by using DD3 promoter to enhance the efficacy and safety of adenovirus. The combined use of DD3-ZD55-SPAG9 and docetaxel showed that DD3-ZD55-SPAG9 significantly improved the anti-tumor efficacy of docetaxel in PCa both in vitro and in vivo. The mechanism was related to the induction of tumor cell apoptosis and the inhibition of tumor cell invasion. In conclusion, DD3-ZD55-SPAG9 combined with docetaxel is an effective strategy for PCa therapy.
前列腺癌（PCa）是男性泌尿系统常见的恶性肿瘤，在肿瘤相关死亡原因中排名第二。差异显示编码3（DD3）是一种在PCa中特异性表达的非编码基因。精子相关抗原9（SPAG9）的高表达与PCa的肿瘤发生密切相关，且SPAG9是PCa的治疗靶点。在本研究中，通过使用DD3启动子构建了一种新型溶瘤腺病毒DD3-ZD55-SPAG9，以提高腺病毒的疗效和安全性。DD3-ZD55-SPAG9与多西他赛联合使用表明，DD3-ZD55-SPAG9在体外和体内均显著提高了多西他赛对PCa的抗肿瘤疗效。其机制与诱导肿瘤细胞凋亡和抑制肿瘤细胞侵袭有关。总之，DD3-ZD55-SPAG9与多西他赛联合使用是PCa治疗的有效策略。
